The effect of anti-phospholipid syndrome on pregnancy outcomes in patients with habitual abortus
DOI:
https://doi.org/10.46328/aejog.v5i2.154Keywords:
antiphospholipid syndrome, pregnancy complication, pregnancy outcomeAbstract
Objective: The aim of this study was to research the pregnancy outcomes of women with anti-beta2 glycoprotein 1 and anti-cardiolipin antibody positivity and to determine the association with pregnancy morbidity.
Materials and methods: This retrospective study contained pregnant women with anti-beta2 glycoprotein 1 and anti-cardiolipin antibody positivity and a control group without these antibodies. Totally 190 serum samples sent from Obstetrics and Gynecology clinics between January 2019 and January 2023 were analyzed in the medical microbiology laboratory of xx.
Results: In a patient population separated into antibody-positive and antibody-negative groups, the gravida was found to be 3.8±0.1 and 3.5±0.3 respectively (p=0.333). Parity was 1.1±0.1 and 0.8±0.1 (p=0.071), abortion rates were 2.3±0.1 and 2.5±0.2 (p=0.659), and gestational age was 35.7±0.8 and 34±1.5 (p=0.047). Intrauterine fetal death was found to be higher in the antibody-positive group compared to the antibody-negative group (p=0.03). There was no noteworthy distinction noted between the two groups regarding additional pregnancy complications such as intrauterine growth restriction, oligohydramnios, gestational diabetes, and gestational hypertension (respectively p=0.623, 0.074, 0.312, 0.626). However, smoking was significantly higher in the antibody-positive group (p=0.049).
Conclusion: Antiphospholipid syndrome adversely affects pregnancy outcomes. During the initial visit, a thorough patient history should be obtained, and in pregnant women with a history of poor obstetric outcomes or habitual abortions, this syndrome should be considered.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Alper Togay, Duygu Tekin , Mehmet Özer, Özden Sıla Kılınç Gönüllü
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AEJOG is an open-access journal which means that through the internet; freely accessible, readable, downloaded, copied, distributed, printed, scanned, linked to full texts, indexed, transferred to the software as data and used for any legal purpose, without financial, legal and technical obstacles. The only authority on reproduction and distribution and the sole copyright role in this field; has been given to authors therefore they can have control over the integrity of their work, so that they are properly recognized and cited. This is in accordance with the BOAI definition of open access.
The content in Aegean Journal of Obstetrics and Gynecology (AEJOG) is protected by copyright. All copyrights of the submitted articles are transferred to the Aegean Journal of Obstetrics and Gynecology within the national and international regulations at the beginning of the evaluation process. Upon submission of their article, authors are requested to complete an assignment of copyright release form. Authors should acknowledge that they will not submit their manuscript to another journal, publish in any other language, or allow a third party to use the article without the written consent of the Aegean Journal of Obstetrics and Gynecology. When an article is published on AEJOG, it is read and reused for free as soon as it is published under a Creative Commons Attribution-NonCommercial 4.0 (CC BY NC 4.0) license. In case the article is rejected, all copyrights are given back to the authors.
The content of the article and all legal proceedings against the journal, if any, are the responsibility of the author. In addition, all financial and legal liability for the copyright of the presented tables, figures and other visual materials protected by law belongs to the authors. It is the responsibility of the corresponding author to report authors scientific contributions and responsibilities regarding the article. In case of any conflict of interest, it is the responsibility of the authors to indicate the conflict of interest in the Disclosure part of the article. Author names will be published as they are listed on the submitted Title page.
